Physician profile
Aaron L Travis
NPI 1134149321
$19,818.31
in general payments reported to CMS, 2019-2025
76 companies · $3,250 in 2025
The $3,250 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,259 · 2020: $1,975 · 2021: $2,734 · 2022: $3,704 · 2023: $3,227 · 2024: $2,670 · 2025: $3,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,756 · Long Term Medical Supply Or Device Loan: $370 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,755.94 |
| Long Term Medical Supply Or Device Loan | $370.36 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.99 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $2,370.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,510.39 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $1,159.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,130.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $809.12 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $739.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $483.72 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.21 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $450.98 | 2020-2024 | Verquvo, Belsomra, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $444.16 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $433.58 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $431.79 | 2019-2025 | |
| Abbott Laboratories | $406.59 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $388.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.